Bernstein downgrades Tandem Diabetes due to market share loss concerns

From Investing.com: 2025-03-03 13:10:57

Bernstein has downgraded Tandem Diabetes due to concerns about the company’s market share loss. The downgrade comes after Tandem reported lower than expected sales figures for its insulin pumps. Bernstein cited increased competition in the diabetes market as a key factor in their decision to lower Tandem’s rating.



Read more at Investing.com: Bernstein downgrades Tandem Diabetes on market share loss concerns